A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes

This randomized, controlled 13-week trial evaluated the efficacy and safety of automated insulin delivery (AID) in adults with insulin-treated type 2 diabetes. Patients were randomized to receive either AID or continue their usual insulin therapy with continuous glucose monitoring. The AID group showed a greater reduction in glycated hemoglobin levels compared to the control group (−0.6 percentage points; P<0.001) and spent significantly more time in the target glucose range. The frequency of hypoglycemia was low in both groups. AID was found to be a safe and effective method to improve glycemic control in this population.

This randomized, controlled 13-week trial evaluated the efficacy and safety of automated insulin delivery (AID) in adults with insulin-treated type 2 diabetes. Patients were randomized to receive either AID or continue their usual insulin therapy with continuous glucose monitoring. The AID group showed a greater reduction in glycated hemoglobin levels compared to the control group (−0.6 percentage points; P<0.001) and spent significantly more time in the target glucose range. The frequency of hypoglycemia was low in both groups. AID was found to be a safe and effective method to improve glycemic control in this population.